Asphyxia, Congenital Heart Disease, Patent Ductus Arteriosus, Preterm, Pulmonary Hypertension, Sepsis, Stroke
Conditions
Keywords
Cerebral Doppler, Monitoring, Continuous, Neonate
Brief summary
Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term/premature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.
Detailed description
A new ultrasound technology called NeoDoppler has been developed, which can measure blood flow in the brain over time. The product is approved for clinical use (CE approved). A pilot study, with with inclusion of different patient groups in need of continuous monitoring, will be conducted to map variability of cerebral hemodynamics. These studies include: 1. A feasibility study on healthy preterm- and term born neonates to map what is normal cerebral blood flow in neonates born before gestational week 32, in gestational week 32-37 and at term. 2. A study including preterm neonates with patent ductus arteriosus to look at the connection between the heart's function and the brain's blood flow. 3. Studies of sick neonates including conditions such as perinatal asphyxia, stroke, pulmonary hypertension and congenital heart disease to study how different medical conditions influences cerebral blood flow. 4. A study on cerebral blood flow during ongoing procedures such as intubation, anesthesia, spinal puncture and peripheral and central arterial- and venous catheter. 5. A study of how infection, sepsis and meningitis affects cerebral blood flow.
Interventions
DEVICENeoDoppler - CE certified
The NeoDoppler is small and light weighed constructed as a single element transducer, that can be gently fixed over the fontanelle. The system is fully compatible for cooccurring use with other intensive care equipment for neonates as well as caregiving from the parents. It is capable of measuring cerebral blood flow at different depths of the brain simultaneously. The Doppler velocity measurements arise from a cylindrical volume of tissue. It is therefore less sensitive to the exact position and angle of the probe over the fontanel to target the vessels of interest than standard hand-held Doppler. This means that the NeoDoppler system may be placed by healthcare professionals who do not have specialized training performing diagnostic ultrasound exams of the cerebral vasculature in neonates.
Sponsors
St. Olavs Hospital
Norwegian University of Science and Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 12 Months
Healthy volunteers
Yes
Inclusion criteria
* Open fontanelle * Healthy preterm or term born neonates * Neonates with a medical condition of interest according to the different cohort studies: patent ductus arteriosus, perinatal asphyxia, stroke, pulmonary hypertension, congenital heart condition or infection/sepsis/meningitis * Neonates in need of procedures
Exclusion criteria
* Caregivers not understanding/speaking Norwegian or English * Caregivers not giving their consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cerebral Doppler velocities (cm/second) | 2 hours - 7 days | Cerebral Doppler velocities measured in cm/sec is generated by tracing of the Doppler spectrum. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement quality | 2 hours - 7 days | Quality indicator: Defined as a scale from 0-100% where 100% is the best possible Doppler spectrum quality. Values below 80% is below the threshold of good enough quality to be used as valid measurements in the study. |
Countries
Norway
Contacts
CONTACTSiri Ann Nyrnes, MD, PhD
CONTACTSiv Steinsmo Ødegård, MD, PhD
PRINCIPAL_INVESTIGATORSiri Ann Nyrnes, MD, PhD
Childrens Clinic, St. Olavs University Hospital and NTNU
STUDY_DIRECTORØyvind Rognmo, PhD
Norwegian University of Science and Technology, Trondheim, Norway
Outcome results
None listed